Sign In
Buy MRK
$115.49
+0.320 (+0.278%)
At Close: Jun 17, 2026
NEW YORK CITY, NY / ACCESS Newswire / March 27, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Merck & Co., Inc. ("Merck" or the "Company") (NYSE:MRK). Such investor
Merck & Co., Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - MRK
04:30pm, Thursday, 27'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws,
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws,
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Merck & Co., Inc. Lawsuit - MRK
01:00pm, Thursday, 27'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws,
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. (NYSE:MRK) between February 3, 2022 and
Investors who lost money on Merck & Co., Inc. (MRK) should contact Levi & Korsinsky about pending Class Action - MRK
12:53pm, Thursday, 27'th Mar 2025
NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK) of a class action securities lawsuit.
NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. (NYSE: MRK) between February 3, 2022 and Febr
Merck Gets EC Nod for 21-Valent Pneumococcal Jab Capvaxive
12:36pm, Thursday, 27'th Mar 2025
The European Commission approves MRK's pneumococcal 21-valent conjugate vaccine, Capvaxive, for pneumococcal vaccination in adults.
Merck & Co (MRK) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
12:00pm, Thursday, 27'th Mar 2025
LOS ANGELES , March 27, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Merck & Co ("Me
Merck plans US to launch subcutaneous version of Keytruda on October 1
11:03am, Thursday, 27'th Mar 2025
Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy Keytruda in the U.S. on October 1, and expects to hit peak adoption rates
RAHWAY, N.J.--(BUSINESS WIRE)-- #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first data presentation from the pivotal 3475A-D77 Phase 3 trial, eva
Levi & Korsinsky Notifies Shareholders of Merck & Co., Inc. (MRK) of a Class Action Lawsuit and an Upcoming Deadline
10:15am, Thursday, 27'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws,
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Merck & Co., Inc. ("Merck" or the "Company") (NYSE:MRK). Such investors are
Is Merck Stock a Bargain Buy?
08:30am, Thursday, 27'th Mar 2025
Merck (MRK 0.32%) is a top healthcare company with one of the best drugs ever made in its portfolio: Keytruda. While there are concerns about its patent losses in the future, its sales are still growi
Levi & Korsinsky Notifies Merck & Co., Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MRK
07:25am, Thursday, 27'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws,
